Pharmacokinetic Study of DYANAVEL XR (Amphetamine) Extended-release Oral Suspension, in Children Aged 4 to 5 Years
Status:
Completed
Trial end date:
2018-05-23
Target enrollment:
Participant gender:
Summary
The objective of this study was to evaluate the plasma amphetamine concentration/time profile
of amphetamine extended release oral suspension in children aged 4 to 5 years with
attention-deficit/hyperactivity disorder, following a single 2.5 mg dose of amphetamine
extended release oral suspension.